These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6331766)

  • 1. Changing patterns of resistance to new beta-lactam antibiotics. In vitro efficacy of cefoperazone against bacterial pathogens.
    Jones RN
    Am J Med; 1984 Jul; 77(1B):29-34. PubMed ID: 6331766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.
    Jones RN; Barry AL; Thornsberry C; Wilson HW
    Am J Clin Pathol; 1985 Oct; 84(4):496-504. PubMed ID: 2994461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibility of major pathogens of orofacial odontogenic infections to 11 beta-lactam antibiotics.
    Kuriyama T; Karasawa T; Nakagawa K; Nakamura S; Yamamoto E
    Oral Microbiol Immunol; 2002 Oct; 17(5):285-9. PubMed ID: 12354209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients.
    Jones RN
    Am J Med; 1996 Jun; 100(6A):3S-12S. PubMed ID: 8678095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing patterns of hospital infections: implications for therapy. Changing mechanisms of bacterial resistance.
    Neu HC
    Am J Med; 1984 Jul; 77(1B):11-23. PubMed ID: 6087659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone.
    Williams JD
    Clin Infect Dis; 1997 Mar; 24(3):494-7. PubMed ID: 9114205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections.
    Patankar M; Sukumaran S; Chhibba A; Nayak U; Sequeira L
    J Assoc Physicians India; 2012 Nov; 60():22-4. PubMed ID: 23767198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
    Medeiros AA; Hare R; Papa E; Adam C; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study on prevalence and molecular mechanisms of antibacterial resistance in Gram-negative pathogens of nosocomial infections in hospitals of Moscow and Perm'].
    Mudrak DE; Ikriannikova LN; Sidorenko SV; Il'ina EN
    Antibiot Khimioter; 2007; 52(7-8):10-6. PubMed ID: 18986019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbial resistance to newer generation beta-lactam antibiotics: clinical and laboratory implications.
    Sanders CC; Sanders WE
    J Infect Dis; 1985 Mar; 151(3):399-406. PubMed ID: 2982957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008).
    Ishii Y; Ueda C; Kouyama Y; Tateda K; Yamaguchi K
    Diagn Microbiol Infect Dis; 2011 Apr; 69(4):443-8. PubMed ID: 21396543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incidence of beta-lactamase-producing pathogens.
    Acar JF; Kitzis MD; Gutmann L
    APMIS Suppl; 1989; 5():2-8. PubMed ID: 2660867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sensitivity to antibiotics of bacteria from nosocomial infections. Evolution in resuscitation services of military hospitals].
    Garrabé E; Cavallo JD; Brisou P; Chapalain JC; Coué JC; Courrier P; Granic G; Hervé V; Koeck JL; Morillon M; Claude JD; Rouby Y; Teyssou R
    Presse Med; 2000 Sep; 29(27):1497-503. PubMed ID: 11045115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. I. Effect of sulbactam against beta-lactams resistant strains and in vitro combined effect of sulbactam/cefoperazone with each of piperacillin, latamoxef, ceftazidime, fosfomycin and doxycycline].
    Kouda M; Kumagai I; Kobayashi J; Sugai R; Matsuzaki H
    Jpn J Antibiot; 1990 Apr; 43(4):636-58. PubMed ID: 2199689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activity of cefoperazone and cefoperazone plus sulbactam in a neutropenic site model.
    Fasching CE; Moody JA; Sinn LM; Tenquist J; Gerding DN; Peterson LR
    Diagn Microbiol Infect Dis; 1991; 14(2):147-55. PubMed ID: 1873973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
    Chen MJ; Wang H;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of cefoperazone/sulbactam in neonates.
    Ovali F; Gursoy T; Sari I; Divrikli D; Aktas A
    Pediatr Int; 2012 Feb; 54(1):60-3. PubMed ID: 21883691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa.
    McLaughlin JC; Barry AL; Fuchs PC; Gerlach EH; Hardy DJ; Pfaller MA
    J Antimicrob Chemother; 1994 Feb; 33(2):223-30. PubMed ID: 8182003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.